About Us | Allterum Therapeutics

ABOUT US. WHAT WE DO

Developing Treatments for CD127 Expressing Cancers

With an initial focus on hematological malignancies, Allterum Therapeutics is developing 4A10, an anti-CD127 monoclonal antibody for treating acute lymphoblastic leukemia (ALL), B-cell malignancies, and lymphomas with CD127 over-expression. Allterum is also exploring relapsed/refractory solid tumors with CD127 over-expression. The 4A10 antibody was developed at the National Cancer Institutes (NCI) and licensed exclusively to Fannin.

Allterum was incubated and launched out of Fannin, an early-stage life science commercialization group, which has assigned its executed license. The company is working with national leaders in cancer at Baylor College of Medicine, Texas Children’s Hospital, the Children’s Oncology Group (COG), the NCI, the Leukemia and Lymphoma Society, and the University of Texas MD Anderson Cancer Center to develop the technology.

OUR MISSION

Continuing the Fight in Hematologic Malignancies

Today, the five-year survival rate for children diagnosed with acute lymphoblastic leukemia (ALL) is over 90% – a result of a lengthy frontline chemotherapy regimen. Unfortunately, not all patients respond so favorably. The patient's subtype of acute lymphoblastic leukemia determines whether or not they have effective standard treatment options available after frontline therapy. Moreover, although ALL is primarily a pediatric disease, with fewer than 20% of new diagnoses in the United States occurring in adults, the prognosis in adults can be even worse than in children.

Patients with relapsed/refractory T-Cell ALL have a critical unmet medical need with poor outcomes and only one new drug (nelarabine) approved in the last fifteen years. Allterum is seeking to change this by developing a targeted therapy for the treatment of patients with relapsed or refractory T-cell ALL and certain B-cell hematologic malignancies.

Exploring Other CD127 Expressing Cancers

Ongoing pre-clinical studies focused on lymphomas and solid tumors will extend Allterum’s clinical program to other metastatic disease with CD127 over-expression where the overall survival is usually less than 20%.

~ 5000

new cases of pediatric ALL each year

~ 1000

new cases of T-cell ALL each year

~ 160

new cases of relapsed/refactory T-cell ALL each year

~ 80000

cases of metastatic disease with CD127 over-expression each year

OUR TEAM

The Allterum team is composed of experienced researchers and entrepreneurs who are supported by well-known organizations and institutions who all share a singular objective: To address an unmet need for pediatric acute lymphoblastic leukemia.